Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.
Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.
“Immunotherapy is regarded as the future of cancer therapy. With Trianta we have secured access to world-class science and innovative therapy platforms with programs that are being evaluated in patients. A truly transforming acquisition!”